SAM #140D0426Q0870

Acquisition of Oxford Nanopore PromethION 2 Integrated Sequencing Platform for NCI Genomics Core

This procurement opportunity is for the acquisition of the Oxford Nanopore PromethION 2 Integrated (P2i) long-read sequencing platform for the National Cancer Institute's Center for Cancer Research Genomics Core. - Government Buyer: - National Cancer Institute, Center for Cancer Research Genomics Core (NIH), procured via the Department of the Interior, Interior Business Center, Acquisition Services Directorate - OEM Highlight: - Oxford Nanopore Technologies is the sole specified OEM for the sequencing platform - Products Requested: - Oxford Nanopore PromethION 2 Integrated (P2i) long-read sequencing platform - Features: Onboard CPU/GPU acceleration, two independently addressable flow cells, real-time sequencing and analysis, Dorado basecalling, methylation detection, demultiplexing, MinKNOW and EPI2ME software integration, high throughput (~290 Gb per flow cell), ultra-long read sequencing, plug-and-play benchtop design - Quantity: 1 unit - Includes 1-year standard support (STANDARD12M-P2I) - Services Requested: - Delivery and installation at the CCR Genomics Core (Bethesda, MD) within 4 to 12 weeks after contract award - Training for NCI researchers on equipment, software, and workflows, to be conducted within one week of installation, with additional training as needed - Notable Requirements: - Platform must be fully integrated with onboard computing (no external workstation required) - Compatibility with existing CCR workflows and consumables - Real-time sequencing and analysis capabilities - Firm-fixed-price contract - Evaluation based on Lowest Price Technically Acceptable (LPTA) - Estimated contract value: $70,000 - No option years or recurring subscription; includes 1-year standard support

Description

Competitive RFQ for the Oxford Nanopore PromethION 2 Integrated sequencing platform, including delivery, installation, training, and support. Evaluation will be LPTA.

View original listing